istock-513551088-handshake
solidcolours / iStockphoto.com
3 May 2017Americas

GSK partners with Bluebird to commercialise gene therapies

GSK and biotech company Bluebird Bio have entered into a licence agreement centring on Bluebird’s lentiviral vector platform.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
20 May 2021   Roche Group’s subsidiary Spark Therapeutics has filed a complaint against rival gene therapy company Bluebird Bio, accusing it of infringing its ‘Spark’ trademark.

More on this story

Big Pharma
20 May 2021   Roche Group’s subsidiary Spark Therapeutics has filed a complaint against rival gene therapy company Bluebird Bio, accusing it of infringing its ‘Spark’ trademark.

More on this story

Big Pharma
20 May 2021   Roche Group’s subsidiary Spark Therapeutics has filed a complaint against rival gene therapy company Bluebird Bio, accusing it of infringing its ‘Spark’ trademark.